Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F19%3A00108625" target="_blank" >RIV/00216224:14110/19:00108625 - isvavai.cz</a>
Result on the web
<a href="https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31835-X/abstract" target="_blank" >https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(19)31835-X/abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.clml.2019.09.448" target="_blank" >10.1016/j.clml.2019.09.448</a>
Alternative languages
Result language
angličtina
Original language name
Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
Original language description
We have performed a face to face comparison of all-oral triplet ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice. The primary endpoint was progression free survival (PFS), secondary end points included response rates and overall survival (OS).
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NV17-29343A" target="_blank" >NV17-29343A: Bone marrow microenvironment analysis in extramedullary relapse of multiple myeloma</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů